Amorphis Pharma Development has filed financial statements for 2 reporting years in the Polish National Court Register (KRS 0000760620), covering 2019–2022. The dashboard below shows the income statement, balance sheet, profitability ratios, valuation indicators and a multi-year comparison against the company's industry benchmark.

Headline figures for the most recent reported year (2022): net revenue 64,112 PLN, net profit 15,359 PLN, total assets 1,047,159 PLN and equity 456,148 PLN. Use the chart toolbar to switch between absolute amounts and indexed series, or to jump straight into the per-year sprawozdanie finansowe.

Derived metrics include ROE, ROA, net and operating margin, the current ratio and the cash ratio, debt-to-equity and asset turnover. Each ratio is plotted alongside the median for Amorphis Pharma Development's PKD activity class, so reading whether the company is above or below the industry takes one glance instead of a side-by-side calculation.